Brief: Akebia Therapeutics And US Renal Care Sign Commercial Supply Contract To Enable Access To Vafseo
07/10/2024 13:37
Oct 7 (Reuters) - Akebia Therapeutics Inc AKBA.O :
* AKEBIA THERAPEUTICS AND U.S. RENAL CARE SIGN COMMERCIAL
SUPPLY
CONTRACT TO ENABLE ACCESS TO VAFSEO® (VADADUSTAT) FOR PATIENTS
ON DIALYSIS
* AKEBIA THERAPEUTICS INC - CONTRACT ENABLES PRESCRIPTION OF
VAFSEO FOR DIALYSIS PATIENTS FROM JAN 2025
* AKEBIA THERAPEUTICS INC - EXPECTS PAYMENT ADJUSTMENT
DESIGNATION
FOR VAFSEO IN JAN 2025
Source text for Eikon: ID:nPn1g2lXFa
Further company coverage: AKBA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Akebia Therapeutics
See all newsAkebia Q1 revenue falls, net income misses analyst estimates on higher expenses
Brief: Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Akebia Therapeutics Appoints Biopharmaceutical Leader Philip Vickers To Its Board Of Directors
Akebia posts wider-than-expected Q4 net loss as higher expenses hurt
Brief: Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule